Stockscreener 앱 받기
63.34
2.85%
-1.86
시간 외 거래:
63.64
0.30
+0.47%
Arcellx Inc 주식(ACLX)의 최신 뉴스
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital - MSN
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8% - MarketBeat
Arcellx Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (ACLX) Movement - Stock Traders Daily
EPS Watch: Can Arcellx Inc stock reach 100 price target2025 Volume Leaders & Community Trade Idea Sharing Platform - moha.gov.vn
Wells starts Arcellx with overweight on multiple myeloma potential - MSN
Arcellx (NASDAQ:ACLX) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program - Yahoo Finance
Wells Fargo initiates coverage of Arcellx (ACLX) with overweight recommendation - MSN
Wells Fargo Initiates Coverage of Arcellx (ACLX) with Overweight Recommendation - Nasdaq
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - Seeking Alpha
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls - Yahoo Finance
Voya Investment Management LLC Reduces Stock Holdings in Arcellx, Inc. $ACLX - MarketBeat
Wells Fargo Initiates Arcellx at Overweight With $100 Price Target - marketscreener.com
Wells Fargo initiates coverage on Arcellx stock with Overweight rating By Investing.com - Investing.com Canada
Wells Fargo initiates coverage on Arcellx stock with Overweight rating - Investing.com
Wells starts Arcellx with Overweight on multiple myeloma potential - TipRanks
Arcellx initiated with an Overweight at Wells Fargo - TipRanks
Can Arcellx Inc. stock continue upward trendJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда
Is Arcellx Inc. stock affected by interest rate hikesQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is Arcellx Inc. stock a defensive play in 2025July 2025 PreEarnings & Technical Entry and Exit Tips - Улправда
How institutional buying supports Arcellx Inc. stock2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Earnings Report: Is Arcellx Inc. stock attractive for hedge funds2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will Arcellx Inc. stock benefit from commodity pricesTake Profit & Breakout Confirmation Trade Signals - Улправда
Why Arcellx Inc. stock could benefit from AI revolutionJuly 2025 Macro Moves & Safe Capital Growth Plans - DonanımHaber
Why Arcellx Inc. stock is recommended by analysts2025 Historical Comparison & Daily Profit Maximizing Trade Tips - DonanımHaber
Dividend Watch: Why Arcellx Inc. stock could see breakout soonDip Buying & AI Powered Buy and Sell Recommendations - Улправда
Technical Reactions to ACLX Trends in Macro Strategies - Stock Traders Daily
Is Arcellx Inc. stock attractive for hedge fundsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Arcellx, Inc. (ACLX) makes progress on multiple myeloma treatment - MSN
Arcellx: Funded Into 2028 With Strong Clinical Data (NASDAQ:ACLX) - Seeking Alpha
Canaccord Genuity Reaffirms Their Buy Rating on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx reports promising phase 2 study results - MSN
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment - Finviz
What Arcellx (ACLX)'s Anito‑cel Phase 2 Data Means For Shareholders - simplywall.st
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Positive Outlook for Arcellx Inc: Buy Rating Backed by Strategic Positioning and Promising CAR T-cell Therapy - TipRanks
Stempoint Capital LP Has $13.27 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Citi Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness By Investing.com - Investing.com South Africa
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness - Investing.com
Cancer Study Buoys These Small Biotechs - Barron's
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025 - ts2.tech
Arcellx shares jump on strong multiple myeloma trial results - MSN
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM - Clinical Trials Arena
Arcellx (ACLX) Valuation Check After Strong Phase 2 iMMagine-1 Results for Anito-cel in Multiple Myeloma - Sahm
Arcellx Inc. Stock Surge: Time to Buy? - StocksToTrade
Arcellx Reports Promising Phase 2 Study Results - TipRanks
0.57%
자본화:
|
볼륨(24시간):